QUANTITY
QUALITY
We’ve created a better database of healthcare M&A data for PE firms, health systems, investment bankers, valuators, attorneys, and dealmakers of all kinds.
HEALTHCARE M&A DATA THAT EXCELS
Click through for more segments
1,700+
Healthcare services transactions since 2010 with deal values and revenue / EBITDA multiples
Ambulatory Surgery Centers
80 with revenue or EBITDA multiples
69 with EBITDA multiples
QUALITY INFORMATION IS GOOD FOR YOU
There’s more publicly-available private market data with reliable deal values and multiples in healthcare than any other industry, it just takes a heavy lift to find it. We maintain a database of links to our sources, which include:
• Fairness opinions
• SEC filings
• Press releases
• Bond market research
• Medicare cost reports
• CON filings (FOIA)
• Form 990s
• Public financial statements
• AG reports
• Insurance department filings
ACCURATE
DATA
SIMPLE
FORMAT
AMPLE
DETAIL
RELIABLE
SOURCES
HEALTHCARE VALUATONS DECADE REVIEW
Healthcare Services M&A Valuations 2010-2019
Scope Research's Healthcare Services M&A Valuations 2010 - 2019 details some of our insights from the past decade of collecting price to revenue and EBITDA multiples from well over 1,000 healthcare services deals. We hope this is a helpful free resource for private equity firms, investment bankers, valuators, corporate development teams, and anyone else involved in healthcare M&A.
CHOOSE YOUR TREATMENT PLAN
1
Annual Subscriptions
24/7 access to entire database
Give your entire team 24/7 access to up-to-date research across all industry segments we cover.
For healthcare M&A professionals of all kinds
2
Individual Reports
Only the segments you want
One-time purchases by the segment to get your team up to speed quickly for specific projects.
For single-use client chargeable projects
ANATOMY OF OUR ANALYSIS
Ensure deal value is accurately stated on a total invested capital basis
Source reliable indications of revenue and EBITDA
Share the resulting
data in an easy to use format with links to sources
U.S. Renal Care
-
In February 2019 a group of private equity sponsors agreed to a leveraged buyout of U.S. Renal Care for a total valuation of $2.7b, according to Moody's
-
U.S. Renal Care’s FY 2018 financial statements, including adjusted EBITDA (less payments to minority investors in subsidiaries) were disclosed publicly in a New York certificate of need filing
Enterprise Value: $2.7b
Revenue Multiple: 2.0x
EBITDA Multiple: 9.3x
WE SUPPORT IMPROVED OUTCOMES
Private Equity Firms
Know your market. Scope's research arms you with more healthcare private market data than anyone else, so your analysts can track industry-wide valuations and easily compare market segments.
Valuation Consulting
Never rely solely on the income approach again. Scope's research makes reliable comparable transaction data readily available so you can develop better supported conclusions.
Corporate Development
The best strategy is an informed one. Scope's research lets your team to dig deeper into specific transactions in your target market to understand how deals are priced and structured.
Attorneys
Always know the facts. Scope's research enables your firm to provide more knowledgeable negotiation support, resolve disputes with facts rather than opinions, and review valuation reports like a pro.
Investment Bankers
Precedent transactions in a minute. Scope's research allows your analysts to visualize market trends at a high-level, get up-to-speed on new segments quickly, and re-focus time on getting the right deal done.
SEE FOR YOURSELF
Scope Research was created by Will Hamilton, a healthcare valuation expert who long suffered from a lack of publicly available healthcare transaction data. Our demos are low pressure, customized, and interactive so you always see what you need to see in the time that you have.
